TerminatedPhase 2NCT02739477
Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen
Studying Ebola hemorrhagic fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
- Principal Investigator
- Daouda Sissoko, DoctorInserm 897 unit, ISPED, Université de Bordeaux, Bordeaux cedex
- Intervention
- Favipiravir(drug)
- Enrollment
- 2 enrolled
- Eligibility
- 18 years · MALE
- Timeline
- 2016 – 2016
Study locations (2)
- Conakry, Conakry, Guinea
- Nzérékoré, Nzérékoré, Guinea
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02739477 on ClinicalTrials.govOther trials for Ebola hemorrhagic fever
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05992480REVIVE (Response to the Ebola Virus Vaccine)Tulane University
- ACTIVE NOT RECRUITINGPHASE2NCT06803342A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy AdultsAlbert B. Sabin Vaccine Institute
- RECRUITINGPHASE3NCT06126822Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRCInstitute of Tropical Medicine, Belgium
- ACTIVE NOT RECRUITINGPHASE2NCT06100913Immunology of Ebola VaccineEmory University